首页/数据集/Increased translation driven by a non-canonical EZH2 cistrome creates a synthetic vulnerability in enzalutamide-resistant prostate cancer

Increased translation driven by a non-canonical EZH2 cistrome creates a synthetic vulnerability in enzalutamide-resistant prostate cancer

NIAID Data Ecosystem2026-05-02 收录

耐药性前列腺癌

EZH2翻译调控

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266956 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

应用场景：

创建时间：

2025-01-21

耐药性前列腺癌

RNA表达谱分析

We established an enzalutamide-resistant C4-2b prostate cell line that has an active androgen receptor by maintaining the C4-2b cell line in serially increasing concentrations of enzalutamide. Among t

NIAID Data Ecosystem90

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence [Cell line ChIP-Seq]

耐药性前列腺癌

昼夜节律表观遗传调控

In prostate cancer, androgen receptor (AR)-targeting agents are very effective in various stages of the disease. However, therapy resistance inevitably occurs and little is known about how tumor cells

NIAID Data Ecosystem70

RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway

耐药性前列腺癌

信号通路

The aim of this research was to confirm the regulatory effect of RUVBL1 on gene expression in castration resistant prostate cancer. In this research, there were six samples examined including samples

NIAID Data Ecosystem50

GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance. GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance

耐药性前列腺癌

雄激素受体信号

Genomic amplification of the androgen receptor (AR) is an established mechanism of antiandrogen resistance in prostate cancer. Here we show that the magnitude of AR signaling output, independent of AR

NIAID Data Ecosystem70

RB-N phosphorylation promotes BRD4-mediated CREB signaling hyperactivation and BET inhibitor resistance

耐药性前列腺癌

靶向治疗联合方案

The combination of CREB inhibitor and JQ1 could overcome the resistance to BET inhibitors in RB loss prostate cancer. Our study firstly showed that GNB1L-CREB pathway was activated after RB loss and c

NIAID Data Ecosystem50

Increased translation driven by a non-canonical EZH2 cistrome creates a synthetic vulnerability in enzalutamide-resistant prostate cancer

资源简介：

相关数据集